DaraPC: 0.5 mg/ml anti-CD38 antibody
Inno-train
DaraEx compound inhibits the agglutination effect of anti-CD38 in IAT without side effects.
Antibody based drugs can disturb serological blood group testing since the examined antigens can be masked by the therapeutic antibodies. An anti-CD38 antibody for treatment of multiple myeloma shows a strong interference in the indirect antiglobulin test (IAT) where most of the reactions turn to unspecifically (wrong) positive. The time consuming standard technique using Dithiothreitol (DTT) counteracts the interference but has major drawbacks like destruction of Kel antigens or hemolysis. The imusyn DaraEx compound inhibits the agglutination effect of anti-CD38 in IAT without side effects.
Features
- Easy to implement in routine serology
- Quick and simple procedure
- Specific inhibition of anti-CD38 reactivity without affecting other antigens or alloantibody reactions
- No side effects like destruction of blood group antigens or hemolysis as described for the standard DTT treatment
- No need for expensive anti-idiotypic antibodies or soluble CD38 protein for blocking anti-CD38
Additional Images
Resources
Would you like to know more ?
Just fill in the details below and we will get one of our helpful team to give you a shout !
Send
© Copyright 2025 - Sussex Biologicals Ltd